Premium
GraniteShares ETF Trust GraniteShares (NVDL)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow FLEMINGTON, N.J., May 10 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) today announced that its...
NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12 FLEMINGTON, N.J., MAY 3 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD: NVDL) , a leading formulator of...
NovaDel Pharma's Third Foreign Patent Issued FLEMINGTON, N.J., April 22 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) said it was awarded Greek Patent No.GR0904055...
NovaDel CEO Interviews on Wall Street Reporter First FDA Approval Filing to Occur Within Next Two Months; Five Tier One Drugs Entering Proof of Concept Studies FLEMINGTON, N.J., April 19...
NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter FEMINGTON, N.J., April 15 /PRNewswire-FirstCall/ -- Gary Shangold, MD, chief executive officer of NovaDel Pharma, Inc. (BULLETIN...
NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting FLEMINGTON, N.J., April 14 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD:...
NovaDel Reports First Quarter 2004 Progress FLEMINGTON, N.J., Apr. 7 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) reported substantial progress in product development...
NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board FLEMINGTON, N.J., March 1 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN...
NovaDel Raises $14 Million in Private Offering New Funding Will Accelerate Human Feasibility Studies of Four Top-Selling Drugs; First NDA Filing Scheduled for Q2-3 FLEMINGTON, N.J., Jan. 12...
NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study FLEMINGTON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -3.99 | -5.55169055239 | 71.87 | 72.55 | 59.77 | 22213223 | 63.7959267 | SP |
| 4 | -12.66 | -15.7188974423 | 80.54 | 81.9 | 59.77 | 16135405 | 69.84088272 | SP |
| 12 | 7.22 | 11.9024068579 | 60.66 | 88.31 | 52.2 | 17501176 | 71.96138887 | SP |
| 26 | -22.63 | -25.0027621257 | 90.51 | 91.625 | 34.28 | 21147821 | 64.34378794 | SP |
| 52 | 51.15835761 | 305.94098604 | 16.72164239 | 91.625 | 13.92942632 | 15635147 | 59.13269154 | SP |
| 156 | 63.4984199 | 1449.21280567 | 4.3815801 | 91.625 | 2.95186885 | 7904481 | 58.12438286 | SP |
| 260 | 63.4984199 | 1449.21280567 | 4.3815801 | 91.625 | 2.95186885 | 7904481 | 58.12438286 | SP |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
